Phase III randomized trials of tyrosine kinase inhibitor (TKI) therapy for EGFR-mutant and anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged lung cancers have shown documented improvements in response and progression-free survival (PFS) [1–3], and TKIs are approved for patients with oncogene-driver mutations. Here, ALK is linked to lung carcinoma.